石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON INNOVATIVE DRUG DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce the updates on innovative drug development of the Group as follows:

1. Progress on SYN045 tablets

As stated in the Company's announcement dated 3 April 2025, the Group's SYN045 tablets, a Type 1 new drug of chemical drug (a highly selective PGI_2 receptor agonist with obvious anti-pulmonary hypertension effects on animals), has obtained approval from the National Medical Products Administration of China for adding three different specifications (10mg, 25mg and 50mg) for Phase I clinical trial.

The Board is pleased to announce that, recently, clinical trial of single administration of SYN045 tablets in 50mg and 100mg specifications and multiple administration of 25mg specifications have been completed. The research has shown good results in human pharmacokinetic characteristics and, as compared with drugs of the same drug target, significant improvements in safety and tolerability which are favourable in achieving long-term oral administration. As of now, a total of 18 invention patents has been submitted for SYN045 project, including 5 international invention patents (submitted for international PCT applications) and 13 domestic invention patents (in which 5 invention patents related to compounds, crystal forms, preparations, etc. have been granted).

Depending on the final results of the Phase I clinical trial, the Group is planning to commence the Phase IIa clinical trial in order to determine the dose-response relationship in the human body and explore the efficacy and safety in the body of patients. The Company will issue an announcement regarding the SYN045 tablets development as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

2. Progress on other new drug development

The Board is also pleased to announce the updates on other new drug development of the Group as follows:

1. Anti-epileptic innovative drug

Being a Type 1 anti-epileptic innovative drug project self-developed by the Group, its drug target is the potassium ion channel KCNQ2/3. Currently, compound screening is commencing, and toxicity assessment is under preparation.

2. Pain treatment innovative drug

Being a Type 1 innovative drug project self-developed by the Group for anti-diabetic peripheral neuropathic pain, its drug target is the adaptor-associated protein kinase 1 (AAK1). Currently, compound screening is commencing.

3. New improved drug

The Group is currently commencing the research on improved formulations of three new drugs, two of which have been completed pharmacokinetic-based prescription studies and the remaining one is planned to submit an Investigational new drug (IND) application this year.

With the plan of accelerating the innovative drug development and the progression of the above innovative drug projects, the Company will issue an announcement regarding the innovative drug development as and when appropriate in accordance with the Listing Rules.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 7 July 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.